A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/5/2019 |
| Start Date: | June 16, 2016 |
| End Date: | November 30, 2020 |
| Contact: | Boehringer Ingelheim Call Center |
| Email: | clintriage.rdg@boehringer-ingelheim.com |
| Phone: | 1-800-243-0127 |
An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia
Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose
for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and
efficacy of BI 836858 in combination with decitabine Phase I Extension: Primary objective is
to collect additional data on safety, pharmacokinetics and efficacy and to define the
Recommended Phase II Dose (RP2D) of BI 836858 in combination with decitabine.
Phase II: Primary objective is to investigate efficacy, safety and pharmacokinetics of BI
836858 in combination with decitabine compared to decitabine monotherapy.
for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and
efficacy of BI 836858 in combination with decitabine Phase I Extension: Primary objective is
to collect additional data on safety, pharmacokinetics and efficacy and to define the
Recommended Phase II Dose (RP2D) of BI 836858 in combination with decitabine.
Phase II: Primary objective is to investigate efficacy, safety and pharmacokinetics of BI
836858 in combination with decitabine compared to decitabine monotherapy.
Inclusion criteria:
- Phase I Dose Escalation:
1. Male or female patients >/= 18 years of age with relapsed or refractory AML
2. Male or female patients >/= 65 years of age with previously untreated AML
ineligible for receiving standard intensive therapy
- Phase I Extension and Phase II:
Male or female patients >/= 65 years of age with previously untreated AML ineligible for
receiving standard intensive therapy
- Histologically or cytologically confirmed AML according to the WHO classification
- Patients must be eligible for treatment with decitabine
- Eastern co-operative oncology group (ECOG) performance score inclusion criteria apply
Exclusion criteria:
- Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M3),
according to WHO classification.
- Patients who are candidates for allogeneic stem cell transplantation.
- Active chronic graft versus host disease requiring immunosuppressive treatment.
- Phase I extension and Phase II only: Prior treatment with a hypomethylating agent,
such as prior treatment for MDS.
- Prior treatment with Cluster of differentiation 33 (CD33) antibody Further exclusion
criteria apply.
We found this trial at
6
sites
Click here to add this to my saved trials
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
Click here to add this to my saved trials
The Ohio State University, Wexner Medical Center Located in Columbus, The Ohio State University Wexner...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials